Mesoblast (ASX:MSB) will issue 10.2 million ordinary shares to Osiris Therapeutics as contingent consideration in relation to the approval of its cell treatment by the US Food and Drug Administration (FDA), according to a Monday Australian bourse filing.
The FDA approved the firm's mesenchymal stromal cell therapy, Ryoncil, in December 2024, according to an earlier filing.
The shares will be subject to voluntary escrow for 12 months from the date of issue, the filing said.
Mesoblast's shares fell 6% during trading on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。